SEC Filing Analysis: UNITED THERAPEUTICS Corp (UTHR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Founder, Chairperson, and CEO of United Therapeutics filed a notice of a proposed $1M stock sale under a pre-arranged 10b5-1 trading plan.
• Market Impact: The transaction is immaterial relative to the company's market capitalization and is unlikely to have a market impact.

Company Information

Field	Value
Company	UNITED THERAPEUTICS Corp
Ticker Symbol	UTHR
CIK	0001082554
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	ROTHBLATT MARTINE A
CIK	0001106578
Title/Position	FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-12-19
Transaction Code	Not Applicable
Security Type	COMMON
Shares Involved	2,000
Price Per Share	$507.07
Total Value	$1,014,143.00
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,014,143.00
% of Market Cap	0.005%
Shares Transacted	2,000
% of Shares Outstanding	0.004%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $20.08 billion, a $1 million transaction is considered routine and financially insignificant.
• Transaction Significance: The sale represents a negligible percentage of both market capitalization (0.005%) and shares outstanding (0.004%), falling far below any threshold for materiality.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is extremely small relative to the company's size and public float. Furthermore, it is being conducted under a 10b5-1 plan adopted on May 2, 2025, indicating it was pre-scheduled and not based on recent non-public information.

Volume & Sentiment

• Expected Volume Impact: Negligible. A 2,000-share transaction will be easily absorbed by the market without affecting trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by long-tenured executives are common for financial planning and diversification and are not typically viewed as a bearish signal.

Additional Context

Transaction Notes

• Special Circumstances: The sale is part of a 10b5-1 trading plan. The filing also details a consistent pattern of sales by the insider over the preceding three months, reinforcing the routine nature of these transactions.